HSIN-YUN SUNSingh N.2020-12-292020-12-2920080924-8579https://www.scopus.com/inward/record.uri?eid=2-s2.0-55649116186&doi=10.1016%2fS0924-8579%2808%2970011-6&partnerID=40&md5=8c4758e51cac474c8a9cbedc3dce9420https://scholars.lib.ntu.edu.tw/handle/123456789/535298Zygomycetes are being increasingly recognised as important opportunistic pathogens in immunocompromised hosts, including transplant recipients. Conflicting data exist with regard to the contribution of newer antifungal agents such as voriconazole as risk factors for zygomycosis. Although survival rates have improved, outcomes in patients with zygomycosis remain suboptimal. Combination antifungal therapies as well as unique interactions of calcineurin inhibitor immunosuppressive agents with antifungals have potentially relevant implications for optimising outcomes in zygomycosis. ? 2008 Elsevier BV.[SDGs]SDG3amphotericin B deoxycholate; amphotericin B lipid complex; anidulafungin; antifungal agent; calcineurin inhibitor; caspofungin; deferasirox; deferiprone; echinocandin; fluconazole; iron; itraconazole; ketoconazole; micafungin; posaconazole; voriconazole; article; clinical trial; cryptococcosis; disease predisposition; drug potentiation; fungus growth; graft recipient; hematopoietic stem cell transplantation; human; iron chelation; mortality; mucormycosis; nonhuman; outcome assessment; priority journal; risk factor; survival rate; treatment outcome; Zygomycetes; Antifungal Agents; Drug Interactions; Humans; Immunocompromised Host; Immunosuppressive Agents; Transplants; Zygomycosisjournal article10.1016/S0924-8579(08)70011-619013334